---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-010791"
form_type: "8-K"
ticker: "WHWK"
cik: "0001422142"
company_name: "Whitehawk Therapeutics, Inc."
filed_at: "2024-03-13T23:59:59+00:00"
generated_at: "2026-06-04T22:05:22.617280+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Aadi Bioscience reports FY2023 revenue $24.4M (+60% YoY); net loss $65.8M

## Summary
- FYARRO net sales $24.4M for FY2023, up 60% YoY; Q4 sales $6.3M (+21% YoY).
- Net loss $65.8M for FY2023 vs $60.5M in 2022; cash $108.8M funding into Q4 2025.
- PRECISION1 trial enrollment on track to complete by May 2024; two-thirds interim analysis expected Q3 2024.
- Phase 2 trials in accelerated endometrial cancer (EEC) and neuroendocrine tumors (NETs) actively enrolling.

## SEC filing metadata
- accession: 0001628280-24-010791
- form_type: 8-K
- ticker: WHWK
- cik: 0001422142
- company_name: Whitehawk Therapeutics, Inc.
- filed_at: 2024-03-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1422142/000162828024010791/0001628280-24-010791-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1422142/000162828024010791/aadi-20240313.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-010791
- JSON: https://secwatch.observer/filing/0001628280-24-010791.json
- Plain text: https://secwatch.observer/filing/0001628280-24-010791.txt

## Key facts
- Earnings Releases
  Whitehawk Therapeutics, Inc. reported Full year ended December 31, 2023 results: revenue $24.4 million, net income -$65.8 million.
  - Period: Full year ended December 31, 2023
  - Revenue: $24.4 million
  - Net income: -$65.8 million
  - Result: reported results
  source text: (EX-99.1) --- Aadi Bioscience Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Corporate Update FYARRO® sales of $6.3 million for Q4 2023 and $24.4 million for FY 2023 representing year-over-year growth of 21% and 60%, respectively Registration-directed PRECISION1 trial of nab-sirolimus in solid tumors with TSC1 or TSC2 inactivating
  evidence_url: https://www.sec.gov/Archives/edgar/data/1422142/000162828024010791/0001628280-24-010791-index.htm
- Earnings Releases
  Whitehawk Therapeutics, Inc. reported Three months ended December 31, 2023 results: revenue $6.3 million, net income -$16.3 million.
  - Period: Three months ended December 31, 2023
  - Revenue: $6.3 million
  - Net income: -$16.3 million
  - Result: reported results
  source text: Total revenue for the quarter ended December 31, 2023, was $6.3 million, and $24.4 million for the full-year ended December 31, 2023, resulting from sales of FYARRO.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1422142/000162828024010791/0001628280-24-010791-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.